Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cell-to-cell
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Multi-target
100%
CD19
100%
Bicistronic
100%
CD22
100%
Relapsed/refractory Diffuse Large B-cell Lymphoma
100%
Pembrolizumab
66%
Complete Response
50%
Confidence Interval
16%
Remission
16%
Response Rate
16%
Overall Response Rate
16%
Neurotoxicity
16%
Partial Response
16%
T Cell Expansion
16%
Complete Responders
16%
Hospital Days
16%
Stage III-IV
16%
Progression-free
16%
Binder
16%
Hemophagocytic Lymphohistiocytosis
16%
Antigen Loss
16%
T Cell Exhaustion
16%
Multi-antigen
16%
95% Confidence Interval
16%
Targeting Cells
16%
Cytokine Release Syndrome
16%
Large B-cell Lymphoma
16%
Durable Remission
16%
Outpatient Administration
16%
Antigen Density
16%
Programmed Cell Death Protein 1 Blockade
16%
Immunology and Microbiology
B Cell
100%
Chimeric Antigen Receptor T-Cell
100%
CD19
100%
CD22
100%
Pembrolizumab
80%
Antigen
40%
Cell Expansion
20%
Progression Free Survival
20%
Hemophagocytic Lymphohistiocytosis
20%
Programmed Death 1 Receptor
20%
Cytokine Release Syndrome
20%
Chimeric Antigen Receptor T-Cell Therapy
20%
T Cell Exhaustion
20%
Medicine and Dentistry
Large-Cell Lymphoma
100%
Chimeric Antigen Receptor T-Cell
100%
Pembrolizumab
80%
Antigen
40%
Progression Free Survival
20%
Cell Expansion
20%
Outpatient
20%
Neurotoxicity
20%
Programmed Death 1 Receptor
20%
Chimeric Antigen Receptor T-Cell Immunotherapy
20%
Cytokine Release Syndrome
20%
Hemophagocytic Syndrome
20%
Diseases
20%
T Cell Exhaustion
20%
Median Follow Up
20%
Pharmacology, Toxicology and Pharmaceutical Science
Large Cell Lymphoma
100%
Chimeric Antigen Receptor
100%
Pembrolizumab
66%
Remission
33%
Antigen
33%
Progression Free Survival
16%
Neurotoxicity
16%
Cytokine Release Syndrome
16%
Hemophagocytic Syndrome
16%
Programmed Death 1 Receptor
16%
Diseases
16%